Wave Of New Leaders Could Reshape Generics Industry
Numerous Major Off-Patent Players Have Announced New Leadership In Recent Months
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
You may also be interested in...
Hikma’s president of injectables, Riad Mishlawi, has been chosen to become the firm’s new CEO from the start of September. The move comes after a period of success in injectables for Hikma, at the same time as the firm attempts to revive the fortunes of its generics business.
Still only six weeks into the job, Teva’s new CEO Richard Francis and his senior team are busy working on a refreshed company strategy, as Teva looks to grow its top line in 2023 for the first time in six years.
Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.